SCHEMBL23795400

SCHEMBL23795400

C[C@@H]1CNCCCN1S(=O)(=O)c1cccc2c(O)ncc(C3CC3)c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 7/20 0.57
▸ ROCK1 Q13464 7/20 0.57
▸ PRKCD Q05655 5/20 0.57
▸ PRKACA P17612 4/20 0.57
▸ PRKD3 O94806 3/20 0.57
▸ PRKCZ Q05513 3/20 0.57
▸ PRKACG P22612 3/20 0.57
▸ PRKACB P22694 3/20 0.57
▸ PLK4 O00444 2/20 0.57
▸ MARK3 P27448 2/20 0.57
▸ PRKAA1 Q13131 2/20 0.57
▸ PKN2 Q16513 2/20 0.57
▸ MARK2 Q7KZI7 2/20 0.57
▸ AURKB Q96GD4 2/20 0.57
▸ PRKD2 Q9BZL6 2/20 0.57
▸ PRKX P51817 2/20 0.57
▸ AURKA O14965 1/20 0.57
▸ DCLK1 O15075 1/20 0.57
▸ PDPK1 O15530 1/20 0.57
▸ MAP4K4 O95819 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30439029 1.00 ROCK2 (0.57) ROCK2ROCK1PRKCDPRKACAPRKD3
SCHEMBL23795301 1.00 ROCK2 (0.57) ROCK2ROCK1PRKCDPRKACAPRKD3
Formic Acid SCHEMBL23795354 0.96 ROCK2 (0.54) ROCK2ROCK1PRKCDPRKACAPRKD3
Formic Acid SCHEMBL23795353 0.96 ROCK2 (0.54) ROCK2ROCK1PRKCDPRKACAPRKD3
SCHEMBL30439325 0.87 ROCK2 (0.55) ROCK2ROCK1PRKCDPRKACAPRKD3
SCHEMBL30439328 0.87 ROCK2 (0.55) ROCK2ROCK1PRKCDPRKACAPRKD3
SCHEMBL23795322 0.87 ROCK2 (0.55) ROCK2ROCK1PRKCDPRKACAPRKD3
SCHEMBL23795320 0.87 ROCK2 (0.55) ROCK2ROCK1PRKCDPRKACAPRKD3
SCHEMBL23795327 0.87 ROCK1 (0.59) ROCK2ROCK1PRKCDPRKACAPRKD3
SCHEMBL23795325 0.87 ROCK1 (0.59) ROCK2ROCK1PRKCDPRKACAPRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264146-B2 Rho kinase inhibitor, method for preparing same and uses thereof BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2025-04-01 — — US claimed
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2022-01-06 — — US claimed
EP-3878846-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF Beijing Increase Innovative Drug Co., Ltd. (CN) 2021-09-15 — — EP claimed
CN-111116555-A Rho kinase inhibitor and preparation method and application thereof 北京盈科瑞创新药物研究有限公司 2020-05-08 — — CN claimed
US-12264146-B2 Rho kinase inhibitor, method for preparing same and uses thereof BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2025-04-01 — — US disclosed
CN-111116555-B Rho kinase inhibitor and preparation method and application thereof 北京盈科瑞创新药物研究有限公司 2023-06-02 — — CN disclosed
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2022-01-06 — — US disclosed
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2022-01-06 — — US disclosed
EP-3878846-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF Beijing Increase Innovative Drug Co., Ltd. (CN) 2021-09-15 — — EP disclosed
EP-3878846-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF Beijing Increase Innovative Drug Co., Ltd. (CN) 2021-09-15 — — EP disclosed
CN-111116555-A Rho kinase inhibitor and preparation method and application thereof 北京盈科瑞创新药物研究有限公司 2020-05-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF ROCK1, RHOA, ROCK2 ROCK2 3/4885ROCK1 1/4885PRKCD 517/4885
US-12264146-B2 Rho kinase inhibitor, method for preparing same and uses thereof ROCK1, RHOA, ROCK2 ROCK2 3/4885ROCK1 1/4885PRKCD 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback